Send the following on WhatsApp
Continue to Chat復發型 CLL/SLL 患者仍可使用 BTK 抑制劑,FDA 核准 Jaypirca 第二適應症! https://geneonline.news/recurrent-cll-sll-patients-can-still-use-btk-inhibitors-fda-approves-jaypirca-for-second-indication/
復發型 CLL/SLL 患者仍可使用 BTK 抑制劑,FDA 核准 Jaypirca 第二適應症! https://geneonline.news/recurrent-cll-sll-patients-can-still-use-btk-inhibitors-fda-approves-jaypirca-for-second-indication/